Kardiovaskuläre Effekte von GLP-1-Rezeptoragonisten

ZUSAMMENFASSUNG

GLP-1-Rezeptoragonisten reduzieren die Häufigkeit kardiovaskulärer Ereignisse bei Patienten mit Diabetes. Dies wird über atheroprotektive Mechanismen vermittelt, wobei bisher unklar ist, inwieweit direkte immunmodulierende und antientzündliche Eigenschaften der Substanzen hierfür verantwortlich sind. GLP-1-Rezeptoragonisten werden für Patienten mit Diabetes und einem hohen kardiovaskulären Risiko unabhängig vom HbA_1c-Wert als Erstlinientherapie empfohlen, was einem Paradigmenwechsel in der Diabetestherapie entspricht. In diesem Beitrag werden die kardiovaskulären Outcomestudien zu den GLP-1-Rezeptoragonisten vorgestellt und die möglichen Wirkmechanismen in den verschiedenen Organsystemen diskutiert.

• Literatur

• 1 International Diabetes Federation IDF Diabetes Atlas 8th Edition. Im Internet https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/134-idf-diabetes-atlas-8th-edition.html Stand: 10.02.2020
• 2 Rao Kondapally Seshasai S, Kaptoge S, Thompson A. et al Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841 doi:10.1056/NEJMoa1008862
• 3 Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008-2017 doi:10.1016/S0140-6736(14)60794-7
• 4 Hess K, Marx N, Lehrke M. Cardiovascular disease and diabetes: the vulnerable patient. Eur Heart J Suppl 2012; 14: B4-B13 doi:10.1093/eurheartj/sus002
• 5 Rawshani A, Rawshani A, Franzén S. et al Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 379: 633-644 doi:10.1056/NEJMoa1800256
• 6 Gaede P, Lund-Andersen H, Parving HH. et al Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591 doi:10.1056/NEJMoa0706245
• 7 ADVANCE Collaborative Group Patel A, MacMahon S. et al Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572 doi:10.1056/NEJMoa0802987
• 8 Duckworth W, Abraira C, Moritz T. et al Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139 doi:10.1056/NEJMoa0808431
• 9 ACCORD Study Group Gerstein HC, Miller ME. et al Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-828 doi:10.1056/NEJMoa1006524
• 10 Meinert CL, Knatterud GL, Prout TE. et al A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 Suppl 789-830
• 11 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471 doi:10.1056/NEJMoa072761
• 12 U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for industry: Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008
• 13 Cefalu WT, Kaul S, Gerstein HC. et al Cardiovascular outcomes trials in type 2 diabetes: Where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 2018; 41: 14-31 doi:10.2337/dci17-0057
• 14 Scirica BM, Bhatt DL, Braunwald E. et al Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326 doi:10.1056/NEJMoa1307684
• 15 White WB, Cannon CP, Heller SR. et al Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335 doi:10.1056/NEJMoa1305889
• 16 Green JB, Bethel MA, Armstrong PW. et al Effect of stagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242 doi:10.1056/NEJMoa1501352
• 17 Pfeffer MA, Claggett B, Diaz R. et al Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373: 2247-2257 doi:10.1056/NEJMoa1509225
• 18 Holman RR, Bethel MA, Mentz RJ. et al Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377: 1228-1239 doi:10.1056/NEJMoa1612917
• 19 Zinman B, Inzucchi SE, Lachin JM. et al Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014; 13: 102 doi:10.1186/1475-2840-13-102
• 20 Wiviott SD, Raz I, Bonaca MP. et al Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357 doi:10.1056/NEJMoa1812389
• 21 Perkovic V, Jardine MJ, Neal B. et al Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-2306 doi:10.1056/NEJMoa1811744
• 22 Neal B, Perkovic V, Mahaffey KW. et al Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657 doi:10.1056/NEJMoa1611925
• 23 Marso SP, Daniels GH, Brown-Frandsen K. et al Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322 doi:10.1056/NEJMoa1603827
• 24 Marso SP, Bain SC, Consoli A. et al Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844 doi:10.1056/NEJMoa1607141
• 25 Hernandez AF, Green JB, Janmohamed S. et al Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018; 392: 1519-1529 doi:10.1016/S0140-6736(18)32261-X
• 26 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130 doi:10.1016/S0140-6736(19)31149-3
• 27 Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: 819-837 doi:10.1016/j.cmet.2013.04.008
• 28 Eng J, Kleinman WA, Singh L. et al Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-7405
• 29 Mann JFE, Ørsted DD, Brown-Frandsen K. et al Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839-848 doi:10.1056/NEJMoa1616011
• 30 Gerstein HC, Colhoun HM, Dagenais GR. et al Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019; 394: 131-138 doi:10.1016/S0140-6736(19)31150-X
• 31 Verma S, Poulter NR, Bhatt DL. et al Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation 2018; 138: 2884-2894 doi:10.1161/CIRCULATIONAHA.118.034516
• 32 Verma S, Bhatt DL, Bain SC. et al Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: Results of the LEADER trial. Circulation 2018; 137: 2179-2183 doi:10.1161/CIRCULATIONAHA.118.033898
• 33 Marx N, Libby P. Cardiovascular benefits of GLP-1 receptor agonism: Is inflammation a key?. JACC Basic Transl Sci 2018; 3: 858-860 doi:10.1016/j.jacbts.2018.11.008
• 34 Htike ZZ, Zaccardi F, Papamargaritis D. et al Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2017; 19: 524-536 doi:10.1111/dom.12849
• 35 Gentilella R, Pechtner V, Corcos A. et al Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?. Diabetes Metab Res Rev 2019; 35: e3070 doi:10.1002/dmrr.3070
• 36 Brown E, Wilding JPH, Barber TM. et al Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev 2019; 20: 816-828 doi:10.1111/obr.12841
• 37 Maloney A, Rosenstock J, Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: Comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther 2019; 105: 1213-1223 doi:10.1002/cpt.1307
• 38 Seghieri M, Christensen AS, Andersen A. et al Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD. Front Endocrinol (Lausanne) 2018; 9: 649 doi:10.3389/fendo.2018.00649
• 39 Armstrong MJ, Gaunt P, Aithal GP. et al Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690 doi:10.1016/S0140-6736(15)00803-X
• 40 Rizzo M, Nikolic D, Patti AM. et al GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis 2018; 1864: 2814-2821 doi:10.1016/j.bbadis.2018.05.012
• 41 Song X, Jia H, Jiang Y. et al Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis. Sci Rep 2015; 5: 10202 doi:10.1038/srep10202
• 42 Almutairi M, Al Batran R, Ussher JR. Glucagon-like peptide-1 receptor action in the vasculature. Peptides 2019; 111: 26-32 doi:10.1016/j.peptides.2018.09.002
• 43 Tashiro Y, Sato K, Watanabe T. et al A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 2014; 54: 19-26 doi:10.1016/j.peptides.2013.12.015
• 44 Gaspari T, Welungoda I, Widdop RE. et al The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. Diab Vasc Dis Res 2013; 10: 353-360 doi:10.1177/1479164113481817
• 45 Verma S, Leiter LA, Mazer CD. et al Liraglutide reduces cardiovascular events and mortality in type 2 diabetes mellitus independently of baseline low-density lipoprotein cholesterol levels and statin use. Circulation 2018; 138: 1605-1607 doi:10.1161/CIRCULATIONAHA.118.036862
• 46 Zelniker TA, Wiviott SD, Raz I. et al Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 2019; 139: 2022-2031 doi:10.1161/CIRCULATIONAHA.118.038868
• 47 Tuttle KR, McKinney TD, Davidson JA. et al Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obes Metab 2017; 19: 436-441 doi:10.1111/dom.12816
• 48 Thomas MC. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes Metab 2017; 43 (Suppl. 01) 2S20-2S27 doi:10.1016/S1262-3636(17)30069-1
• 49 Nauck MA, Meier JJ, Cavender MA. et al Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017; 136: 849-870 doi:10.1161/CIRCULATIONAHA.117.028136
• 50 Lønborg J, Vejlstrup N, Kelbæk H. et al Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 1491-1499 doi:10.1093/eurheartj/ehr309
• 51 Nauck MA, Tornøe K, Rasmussen S. et al Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diab Vasc Dis Res 2018; 15: 465-468 doi:10.1177/1479164118783935
• 52 Margulies KB, Hernandez AF, Redfield MM. et al Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial. JAMA 2016; 316: 500-508 doi:10.1001/jama.2016.10260
• 53 Lepore JJ, Olson E, Demopoulos L. et al Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail 2016; 4: 559-566 doi:10.1016/j.jchf.2016.01.008
• 54 Consoli A, Formoso G, Baldassarre MPA. et al A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf 2018; 17: 293-302 doi:10.1080/14740338.2018.1428305
• 55 Husain M, Birkenfeld AL, Donsmark M. et al Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381: 841-851 doi:10.1056/NEJMoa1901118